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For people who received their introduction to cancer genetics in college in the ﬁ rst half of the 
1990s, everything looked simple and 
straightforward. It was the stuff you 
could explain to sincerely interested 
relatives who wanted to know what 
you were spending your time on. 
There were oncogenes and there were 
tumour suppressor genes. Oncogenes 
were overactive genes and proteins 
that somehow caused cancer because 
they were overactive; therefore, they 
were dominant. Tumour suppressor 
genes were genes that would normally 
prevent a tumour from happening 
and that needed to be inactivated 
for a tumour to start to form; both 
copies of a tumour suppressor 
gene had to be inactivated, and the 
mutation was recessive. If inactivation 
of these genes is a random process, 
it was understandable that people 
who inherit an inactivated copy of a 
tumour suppressor gene had a higher 
risk of developing the associated 
form(s) of cancer than people born 
with two normal copies, as postulated 
in Alfred Knudson’s (1971) two-hit 
model. And, indeed, it was shown that 
in the tumours in these predisposed 
patients, the remaining wild-type copy 
of the tumour suppressor gene was 
lost, a process referred to as loss of 
heterozygosity.
For me, in 1998 things started to 
change. Venkatachalam et al. (1998) 
published a paper in the EMBO Journal  
describing a detailed study of tumours 
in mice lacking one copy of the p53 
tumour suppressor gene (Trp53). This 
gene is known to be the most mutated 
gene in human cancer and its function 
to be central to many processes that 
are involved in the cellular prevention 
of cancer. Mice lacking both copies of 
this gene are for the most part viable, 
but succumb to cancer (mainly thymic 
lymphomas) at three to ﬁ ve months 
of age (Donehower et al. 1992). Mice 
born with one copy of the Trp53 gene 
start to develop cancer at around nine 
months, and incidence increases with 
age. 
In their study, Venkatachalam and 
colleagues analysed an impressive 
group of 217 Trp53 +/− mice of 
controlled genetic background and 
followed the fate of the Trp53 wild-type 
allele in the tumours. According to the 
two-hit model, it was expected that in 
these tumours this copy would have 
been lost or inactivated. However, this 
turned out not to be the case. Half 
of the tumours from mice younger 
than 18 months were found to have 
retained the wild-type copy of Trp53, 
a number that increased to 85% in 
mice older than 18 months. In two 
tumours, the researchers sequenced 
the complete coding region of the 
remaining wild-type allele and showed 
it was structurally intact. To exclude 
the possibility of downregulation or 
inactivation at the level of protein 
expression, they irradiated tumour-
bearing mice prior to sacriﬁ ce, a 
treatment known to increase p53 
protein levels via posttranslational 
mechanisms. Their data showed the 
retained wild-type allele in these 
tumours was expressed normally and 
suggested it had a normal wild-type 
conformation. 
Next, the authors did a rigorous 
test of different functions of the p53 
protein. They ﬁ rst tested whether 
the tumours showed ampliﬁ cation of 
Mdm2. This protein, whose expression 
is regulated by p53, stimulates 
breakdown of p53, thereby forming 
a negative feedback mechanism that 
keeps p53 levels low. Some tumours 
therefore amplify the Mdm2 gene as a 
means of inactivating p53. However, 
this was not found in the tumours from 
the Trp53 +/− mice. Subsequently, the 
researchers tested to what extent the 
retained Trp53 copy behaved normally. 
Irradiation of many tissues leads to 
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Figure 1. Initiating Genetic Aberrations in Tumourigenesis
(A) According to the two-hit model, the ﬁ rst hit at the rate-limiting tumour suppressor 
gene provides no selective advantage for the cell. Only after the loss of the second 
allele of this gene is tumour formation initiated. Extra genetic changes are needed for 
complete transformation of the cell. 
(B) In a haploinsufﬁ cient mechanism, the ﬁ rst hit on the rate-limiting tumour 
suppressor gene already provides the cell with sufﬁ cient selective advantage to initiate 
tumour formation. Further events are necessary for complete transformation. These 
events might or might not include the loss of the wild-type allele of the rate-limiting 
tumour suppressor gene.
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p53-dependent apoptosis, and, indeed, 
in tumours that had retained the 
wild-type allele, irradiation did lead 
to an increase in apoptosis, whereas 
in tumours that had lost the wild-type 
allele, it did not. 
The p53 protein is known to function 
as a transcriptional regulator by either 
up- or downregulating target genes in 
response to different forms of cellular 
stress, including irradiation-induced 
DNA damage. The authors studied 
the expression of two p53-upregulated 
genes (Cdkn1a, which encodes p21, 
and Mdm2) and one downregulated 
gene (Pcna) in p53-positive tumours 
after irradiation and showed responses 
indicative of normal p53 function. 
Furthermore, it was shown that the p53 
protein from the tumours was able to 
bind to a p53-binding DNA sequence 
in an in vitro setting. Finally, since it 
is known that p53 absence in tumours 
is correlated with chromosomal 
instability, Venkatachalam et al. 
(1998) used comparative genome 
hybridisation to compare this feature 
between p53-negative and p53-positive 
tumours and found a 5-fold greater 
stability in the latter.
In short, this paper clearly showed 
that, at least in mice, in many Trp53 +⁄− 
tumours the wild-type allele of 
Trp53 is not only retained, but also 
appears to function normally. This 
strongly suggested that a decrease 
of dosage in p53 is already sufﬁ cient 
for tumourigenesis, a phenomenon 
referred to as haploinsufﬁ ciency. 
Shortly before, the group of Moshe 
Oren (Gottlieb et al. 1997) had shown 
that a Trp53 +/− background leads 
to a greater than 50% reduction in 
p53 activity using a p53-responsive 
lacZ reporter gene in transgenic 
mice. Venkatachalam and colleagues 
suggested the strong concentration 
dependence of p53 function could be 
explained by the fact that p53 functions 
as a tetramer. A 50% decrease in p53 
monomers can easily be imagined to 
result in a greater than 50% decrease 
in functional tetramers, which in turn 
increases the chances of these cells 
becoming cancerous.
This paper by Venkatachalam et al. 
(1998) made me realise how important 
it is to remain critical, even of long-
established theories and models. Since 
then, haploinsufﬁ cient mechanisms 
have been described in more tumour 
suppressor genes in humans and mice 
(reviewed in Fodde and Smits 2002). 
For instance, in a recent paper in PLoS 
Biology, Trotman et al. (2003) used 
mouse models to describe how the 
dosage of the Pten tumour suppressor 
gene inﬂ uences the occurrence of 
prostate cancer. Further genes have 
been described with other unexpected 
roles in the tumourigenic process. 
There is a long-standing debate in the 
literature about the number and role 
of mutations in a tumour, and without 
going into the details, it is clear that 
haploinsufﬁ cient mechanisms for 
tumour suppressor genes will greatly 
inﬂ uence the statistics on which these 
discussions are based. At a time when 
microarray analysis has become a 
standard experiment and the many 
thousands of changes in tumour cells 
are analysed across the whole genome, 
it is important to keep in mind that 
the correct interpretation of this 
wealth of information might be more 
complicated than the widely accepted 
models would have us believe. 
References
Donehower LA, Harvey M, Slagle BL, McArthur 
MJ, Montgomery CA, et al. (1992) Mice 
deﬁ cient for p53 are developmentally normal 
but susceptible to spontaneous tumours. Nature 
356: 215–221.
Fodde R, Smits R (2002) Cancer biology: A matter 
of dosage. Science 298: 761–763.
Gottlieb E, Haffner R, King A, Asher G, Gruss P, et 
al. (1997) Transgenic mouse model for studying 
the transcriptional activity of the p53 protein: 
Age- and tissue-dependent changes in radiation-
induced activation during embryogenesis. 
EMBO J 16: 1381–1390.
Knudson AG Jr (1971) Mutation and cancer: 
Statistical study of retinoblastoma. Proc Natl 
Acad Sci U S A 68: 820–823.
Trotman LC, Niki M, Dotan ZA, Koutcher JA, 
Cristofano AD, et al. (2003) Pten dose dictates 
cancer progression in the prostate. PLoS Biol 1: 
DOI:10.1371/journal.pbio.0000059.
Venkatachalam S, Shi YP, Jones SN, Vogel H, 
Bradley A, et al. (1998) Retention of wild-type 
p53 in tumors from p53 heterozygous mice: 
Reduction of p53 dosage can promote cancer 
formation. EMBO J 17: 4657–4667.
e
